Description
GenJet™ DNA In Vitro
Transfection Reagent for LNCap is pre-optimized for transfecting
LNCap cells. LNCap cells are a cell line of human cells commonly used in
the field of oncology. LNCaP cells are androgen-sensitive human prostate
adenocarcinoma cells derived from the left supraclavicular lymph node metastasis
from a 50-year-old caucasian male in 1977. They are adherent epithelial
cells growing in aggregates and as single cells.
Refer to the following optimal transfection conditions for maximal transfection
efficiency on LNCap cells. GenJet™ reagent, 1.0 ml, is sufficient for 300 to
600 transfections in 24 well plates or 50 to 100 transfections in 6 well plates.
|
Summary of
Optimal Transfection Conditions:
Confluence on the
day of transfection
Cell culture
conditions
GenJet™ (µl) : DNA (µg) Ratio
Diluent for DNA and Transfection Reagent
Incubation Time to Form GenJet™/DNA
Complex
Presence of Serum/Antibiotics
during Transfection
Change Medium After Transfection
Maximal Efficiency
Transfection
Results:
Reporter Gene
Plasmid
Efficiency (GFP %) |
95%
DMEM with 4.5 g/L glucose, 10% FBS
3:1
Serum-free DMEM with 4.5 g/L glucose
15 minutes at RT
Yes
No
48 hours
EGFP
pEGFP-N3 (CMV promoter)
80% |
Storage Condition
Store at 4 °C. If stored properly, the product is stable for 12 months or longer
GenJet™ reagent is
optimized for LNCap
cells. LNCap cells were
grown per ATCC recommended culture medium and transfected with pEGFP-N3 by
GenJet™ (Ver. II). The efficiency was checked 48 hours post transfection
Data Sheet
